The combination of polymeric materials and prodrug chemistry has reformed drug delivery by presenting specific, precise, and targeted therapeutic release. This review provides the informations on progresses in polymeric materials for prodrug design, focusing on their importance in improving bioavailability, pharmacokinetics, and site-specific activation. Polymers play role as dedicated carriers that enhance solubility, stability, and biocompatibility while shortening toxicity. Novel polymeric designs, such as stimuli responsive micelles, nanogels, and amphiphilic conjugates coordinated release as a response to the stimuli: pH, enzyme, or redox potential gradient, mostly in cancer and inflammatory disease therapy. Prodrug approaches including carrier-linked, bio-precursor, and site-specific designs are deliberated in light of enzyme-activated, photo, and radiotherapy responsive systems. Challenges persist in large scale synthesis, clinical translation, and patient specific differences. Impending directions highlight the merging of artificial intelligence, regenerative medicine, and bioorthogonal chemistry to create personalized and multifunctional polymer-prodrug delivery systems that can significantly boost therapeutic precision.
Artificial-intelligence (AI) is transforming the pharmaceutical industry by simplifying data-driven innovations in drugs’ research and delivery systems. This paper examines and views the newinnovations in combining the use of AI into harmonized medication design and targeted delivery systems. AI-driven models speed-up molecular design, predict pharmacokinetic outcomes, and improve the nanocarrier preparations, reducing the costs and time associated to conventional experimental techniques. Furthermore, AI contentsmake use of computational chemistry and synthesis-based science, improving medicinal effectiveness, precision, and controlled release. It highlights ethical implications and the interaction between computational intelligence and chemical innovation as a means to advance next-generation intelligent therapies and precision medicine. Also, it analyzes AI-driven molecular design with synthetic level reports, emphasizing explainable AI, digital twin platforms, and translations that characterize the next generation of precision pharmaceuticals, distinguishing it from previous narrative reviews.
